Boehringer Ingelheim prepares schizophrenia app for FDA submission after trial results The app targets symptoms like lack of motivation and inability to experience pleasure

https://www.statnews.com/2025/12/05/boehringer-schizophrenia-app-trial-data-fda-submission/ By Mario AguilarDec. 5, 2025 Health Tech Correspondent